Search - Archive ouverte HAL Access content directly

Filter your results

22 Results
authFullName_s : Sophie Park
Image document

A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome

Sabrina Bondu , Anne-Sophie Alary , Carine Lefevre , Alexandre Houy , Grace Jung et al.
Science Translational Medicine, 2019, 11 (500), pp.eaav5467. ⟨10.1126/scitranslmed.aav5467⟩
Journal articles inserm-02449216v1
Image document

Efficacy of Azacitidine in Autoimmune and Inflammatory Disorders associated with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Jean-Baptiste Fraison , Arsène Mekinian , Eric Grignano , Jean-Emmanuel Kahn , Jean-Benoit Arlet et al.
Leukemia Research, 2016, 43, pp.13-17. ⟨10.1016/j.leukres.2016.02.005⟩
Journal articles hal-01278608v1

Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study

Arsène Mekinian , Eric Grignano , Thorsten Braun , Olivier Decaux , Eric Liozon et al.
Rheumatology, 2016, 55 (2), pp.291--300. ⟨10.1093/rheumatology/kev294⟩
Journal articles hal-01299293v1
Image document

Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.

Gandhi Damaj , Alain Duhamel , Marie Robin , Yves Beguin , Mauricette Michallet et al.
Journal of Clinical Oncology, 2012, 30 (36), pp.4533-40. ⟨10.1200/JCO.2012.44.3499⟩
Journal articles inserm-00821506v1

Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.

Gandhi Damaj , Rémy Gressin , Krimo Bouabdallah , Guillaume Cartron , Bachra Choufi et al.
Journal of Clinical Oncology, 2013, 31 (1), pp.104-10. ⟨10.1200/JCO.2012.43.7285⟩
Journal articles inserm-00868869v1

Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia

Aline Renneville , Philippe Attias , Xavier Thomas , Cecile Bally , Sandrine Hayette et al.
Leukemia, 2018, 32 (9), pp.2066-2069. ⟨10.1038/s41375-018-0137-6⟩
Journal articles hal-02343942v1

Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes

Meunier Mathieu , Chloé Friedrich , Nicolas Ducrot , Johanna Zannoni , Tondeur Sylvie et al.
Annals of Hematology, 2022, 101 (12), pp.2633-2643. ⟨10.1007/s00277-022-04993-7⟩
Journal articles inserm-03874959v1

Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes

Meunier Mathieu , Chloé Friedrich , Nicolas Ducrot , Johanna Zannoni , Tondeur Sylvie et al.
Annals of Hematology, 2022, 101 (12), pp.2633-2643. ⟨10.1007/s00277-022-04993-7⟩
Journal articles hal-03876188v1

A Randomised Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS or Low Blast AML: GFM's "Pick a Winner" Trial, with the Impact of Somatic Mutations

Lionel Adès , Nicolas Duployez , Agnes Guerci-Bresler , Kamel Laribi , Pierre Peterlin et al.
British Journal of Haematology, 2022, 198 (3), pp.535--544. ⟨10.1111/bjh.18193⟩
Journal articles hal-03740498v1

Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis

Odile Beyne-Rauzy , Marie Sebert , Rosa Sapena , Hacène Zerazhi , Laurence Legros et al.
British Journal of Haematology, 2016, 175 (5), pp.975-979. ⟨10.1111/bjh.13902⟩
Journal articles hal-01453321v1

Increased S100A8 expression in bone marrow plasma by monocytic cells from acute myeloid leukemia patients

Julie Mondet , David Laurin , Caroline Lo Presti , Marie‐christine Jacob , Mathieu Meunier et al.
Hematological Oncology, 2020, ⟨10.1002/hon.2707⟩
Journal articles hal-03969646v1

Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes

Mathieu Meunier , Sarah Ancelet , Christine Lefebvre , Josyane Arnaud , Catherine Garrel et al.
Oncotarget, 2017, 8 (62), ⟨10.18632/oncotarget.22299⟩
Journal articles hal-01929396v1

IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia

Nicolas Chapuis , Sophie Park , Laurent Leotoing , Jerome Tamburini , Frederique Verdier et al.
Blood, 2010, 116 (20), pp.4240-4250. ⟨10.1182/blood-2009-12-260711⟩
Journal articles pasteur-03277054v1

Extracellular vesicles from myelodysplastic mesenchymal stromal cells induce DNA damage and mutagenesis of hematopoietic stem cells through miRNA transfer

Mathieu Meunier , Audrey Guttin , Sarah Ancelet , David Laurin , Johanna Zannoni et al.
Leukemia, 2020, 34 (8), pp.2249-2253. ⟨10.1038/s41375-020-0738-8⟩
Journal articles hal-03969633v1
Image document

NOX4 is the main NADPH oxidase involved in the early stages of hematopoietic differentiation from human induced pluripotent stem cells

Julie Brault , Bénédicte Vigne , Mathieu Meunier , Sylvain Beaumel , Michelle Mollin et al.
Free Radical Biology and Medicine, 2020, S0891-5849(19)31571-0 (146), pp.107-118. ⟨10.1016/j.freeradbiomed.2019.10.005⟩
Journal articles hal-02355165v1

Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

Valeria Santini , Jennifer Schemenau , Alessandro Levis , Enrico Balleari , Rosa Sapena et al.
Blood, 2013, 122 (13), pp.2286-8. ⟨10.1182/blood-2013-07-512442⟩
Journal articles hal-00868884v1

Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.

Shanti Natarajan-Amé , Sophie Park , Lionel Ades , Norbert Vey , Agnès Guerci-Bresler et al.
British Journal of Haematology, 2012, 158 (2), pp.232-7. ⟨10.1111/j.1365-2141.2012.09153.x⟩
Journal articles hal-00771197v1
Image document

Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes

Sophie Park , Olivier Kosmider , Fréderic Maloisel , Bernard Drénou , Nicolas Chapuis et al.
Haematologica, 2019, 104 (3), pp.497-504. ⟨10.3324/haematol.2018.203158⟩
Journal articles hal-02351432v1

Flow cytometric analysis of neutrophil myeloperoxidase expression in peripheral blood for ruling out myelodysplastic syndromes. A diagnostic accuracy study.

Tatiana Raskovalova , Marc Berger , Marie-Christine Jacob , Sophie Park , Lydia Campos et al.
Haematologica, 2019, 104 (12), pp.2382-2390. ⟨10.3324/haematol.2018.202275⟩
Journal articles hal-02180586v1

Efficacy of Azacitidine (AZA) in Autoimmune and Inflammatory Disorders (AID) Associated with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Jean-Baptiste Fraison , Arsène Mekinian , Eric Grignano , Jean-Emmanuel Kahn , Jean-Benoît Arlet et al.
Blood, 2015, 126 (23), pp.1695
Journal articles hal-01300814v1

Impact of transfusion on survival in patients with myelodysplastic syndromes: Current knowledge, new insights and transfusion clinical practice

Eléonore Kaphan , David Laurin , Bruno Lafeuillade , Philippe Drillat , Sophie Park et al.
Blood Reviews, 2020, 41, pp.100649. ⟨10.1016/j.blre.2019.100649⟩
Journal articles hal-03969638v1

A variant erythroferrone disrupts iron homeostasis in SF3B1 -mutated myelodysplastic syndrome

Sabrina Bondu , Anne-Sophie Alary , Carine Lefèvre , Alexandre Houy , Grace Jung et al.
Science Translational Medicine, 2019, 11 (500), ⟨10.1126/scitranslmed.aav5467⟩
Journal articles hal-03951768v1